Thus, specific mutations were identified more commonly in female CRC patients (such as PIK3CA) or exclusively in these patient subgroups (VEGF polymorphism, variant 936, or the methylation in the 5′ position of the tumor suppressor gene p161NK4a) [38,39,40]. This evidence concerns the gene VEGFA and colorectal carcinoma.